AACR 2026: GenFleet Therapeutics Presents Preclinical Data of GFS784 (EGFR-Pan-RAS ADC), the First Asset from Its Innovative FAScon™ ADC Platform, Demonstrating Potent Activity in RAS-Mutant, EGFR-Mutant and TKI-Resistant Tumors at AACR 2026
File
20260422 e.pdf
